Atlas Trials

A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation

Clinical trial NCT07381114 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07381114
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
aGVHD
Start date
2026-02-14
Primary completion
2026-12-30
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.